Bicyclams represent a novel class of selective anti-HIV inhibitors with potent activity against T-cell tropic strains of HIV. The prototype compound, the bicyclam AMD3100, has an EC 50 of 1 to 10 ng/ml against different strains of HIV-1, including clinical isolates. AMD3100 was shown to interact with the CXCchemokine receptor CXCR4, the main coreceptor used by T-cell tropic strains of HIV. Here we describe the interaction of different bicyclam derivatives with CXCR4. A close correlation (r 2 = 0.7) was found between the anti-HIV potency of the bicyclams and their ability to inhibit the binding of anti-CXCR4 monoclonal antibody or the intracellular Ca 2+ signal induced by the stromal cell-derived factor-1α, the natural ligand of CXCR4. These results indicate that the mechanism of action of the bicyclams is primarily mediated by their interaction with CXCR4. The most potent interaction with CXCR4, and thus anti-HIV activity was shown by bicyclam analogs with cyclam rings composed of fourteen members that are linked by an aromatic (phenyl) bridge. Elucidating the structural requirements for receptor interaction and the site(s) of interaction of bicyclams with CXCR4 will aid in the understanding of HIV-cell fusion. Volumen 55, 1999, p: 67-73 Capítulo 4 104
ACTIVITY OF DIFFERENT BICYCLAM DERIVATIVES AGAINST HUMAN IMMUNODEFICIENCY VIRUS DEPENDS ON THEIR INTERACTION WITH THE CXCR4 CHEMOKINE RECEPTOR INTRODUCTION
The discovery of cellular cofactors involved in the entry of HIV into the host cell has renewed the interest in the early steps of virus replication as a target for therapeutic intervention (Cohen, 1997) . These cofactors are selectively used by different HIV strains and belong to the family of G protein-coupled, seven-transmembrane proteins that function as receptors for chemokines (Deng et al., 1996 , Feng et al., 1996 . to enter their host cells (Feng et al., 1996 , Oberlin et al., 1996 . Small molecules such as AMD3100 that can be readily synthesized and easily administered may have a clear advantage for clinical development. Moreover, the understanding of the mode of action of AMD3100 and bicyclams in general may help to develop newer anti-HIV agents directed to CXCR4 or other chemokine coreceptors used by HIV to enter the cells.
Bridger et al., (1995) and Joao et al., (1995) have shown that the antiviral activity of bicyclam analogs is restricted to the presence of two macrocyclic structures of 12 to 14 members per cyclam ring although identical rings are not required.
Furthermore, the distance between the two macrocyclic rings as reflected by the length of the linker and specific substitutions on the phenylenebis-(methylene) linker are important requirements for the anti-HIV potency of bicyclams. The structural requirements for the anti-HIV activity of the bicyclam analogs are summarised in Table   1 .
In this study we investigate the previous structure-function relationship of the bicyclam analogs for their interaction with CXCR4. From a comparative analysis of the structure-function relationship of the bicyclams, for their interaction with CXCR4 and their anti-HIV activity, we conclude that the anti-HIV activity of the bicyclam derivatives primarily depends on their affinity for CXCR4. 
Requirements
• molecules require two chelating macrocyclic rings for high activity
• distance between metal-binding centers must be 9.5 -11.5 Å
• plane torsion of -60 to 30º and 120-140º are allowed
• plane angles of 40-70º and 110-140º are allowed
• maximize metal affinity for each macrocyclic ring
• optimum ring size for cyclam rings: 14 atoms
Features to avoid
• plane torsion of 70 to 110º
• plane angles 0 to 35º and 160 to 180º
Adapted from Joao et al., (1995) .
MATERIALS AND METHODS
Compounds. The bicyclam analogs described in Fig. 1a , 1b and Fig. 2 were synthesised at Johnson Matthey (West Chester, PA) as described previously (Bridger et al., 1995 . The chemokine SDF-1α was purchased from R&D Systems (Abingdon, UK).
Antiviral assay and cytotoxicity assay. Anti-HIV activity and cytotoxicity measurements in MT-4 cells (Harada et al., 1985) were based on viability of cells that had been infected or not infected with HIV-1 exposed to various concentrations of the test compound. After the MT-4 cells were allowed to proliferate for 5 days, the number of viable cells was quantified by a tetrazolium-based colorimetric method (MTT method) as described by . Anti-HIV activity in SUP-T1 cells (Smith et al., 1984) was based on inhibition of HIV-1 induced cytopathic effect observed microscopically. Anti-HIV activity in MAGI-CCR5 cells (Chackerian et al., 1997) was determined as follows: cells (1x 10 5 /ml) were infected with 3000 ng/ml of compound. Five days after infection, the cells were washed with phosphate-buffered saline (PBS) and evaluated for β-galactosidase activity as described earlier 
RESULTS
Antiviral activity of bicyclams against HIV-1 strains. The antiviral activity, as measured by the MTT method ) is shown for a series of bicyclam analogs ( Table 2 ). The prototype compound AMD3100 proved to be the most potent Modifications of the phenyl linker of AMD3100 had various effects on the anti-HIV activity against the NL4-3 strain of HIV; inclusion of substituents attached to the aromatic ring in the linker (compounds AMD3068, AMD3196, AMD3128, AMD3203, AMD3207, AMD3208 and AMD3209) resulted in reduced or no antiviral activity. This effect was less if at least two substituents (compounds AMD3207, AMD3166 were 4-fold and 7-fold less active than AMD3100, respectively) or four substituents (compounds AMD3070 was 18-fold less active than AMD3100) were included in the phenyl linker. The reason for reduced activity of these bicyclam analogs appears to result purely from steric hindrance effects and restricted rotation of the macrocyclic rings upon the size of the substituent as demonstrated previously (Bridger et al., 1995) .
Alteration of the disposition of nitrogen atoms in the macrocycles also had a detrimental effect on the anti-HIV potency of the compounds: AMD6037 and AMD6038 were less active than AMD3100 (40-fold and 8-fold, respectively). were evaluated against the R5 strain BaL. Only AMD3479 (the zinc complex of AMD3100) was active against HIV-1 BaL albeit at a 1000-fold higher EC 50 of that required to inhibit NL4-3 replication (Table 2) .
Antiviral activity of bicyclams against the AMD3100-resistant NL4-3 strain.
The AMD3100-resistant NL4-3 strain showed reduced sensitivity to AMD3100 (82-fold resistance as compared with the wild type strain) and was insensitive to SDF-1α at its highest concentration tested (2 µg/ml). The resistant virus was also cross-resistant to all the bicyclam analogs tested, although with different magnitudes. The AMD3100-resistant strain could replicate in the presence of the most potent compounds, as it showed reduced sensitivity to the drugs (43-fold, 33-fold, 12-fold, 19-fold, and 66-fold, against AMD3479, AMD3462, AMD3207, AMD3166 and AMD6038, respectively) ( Table 2 ). Compounds with lesser activity against the wild type strain were also less active (AMD3109, AMD3070, AMD3068, and AMD3196 were 50-, 5-, 21-and 89-fold less active, respectively), or became completely inactive (AMD3128, AMD2763, AMD3209, AMD3120, AMD3208, AMD3158, AMD3469, AMD3390, AMD3461 and AMD6037) against the AMD3100-resistant strain. Notably, compound AMD3203 was only 2-fold less active against the AMD3100-resistant strain. Table 2 (♦).
Effect of metal complexes to AMD3100. For transition metal complexes of the prototype AMD3100, the anti-HIV-1 activity depended on the bound metal ( Table 3 ).
The Zn 2+ complex (AMD3479) was slightly more active (10-fold) than AMD3100; and the Ca 2+ flux induced by SDF-1α indicating the dependence on the interaction of metalcomplexed bicyclams with CXCR4 for their respective anti-HIV activity. Resistance to AMD3100 was mapped to the envelope gp120 molecule. Several mutations leading to amino acid substitutions were found in the V3-V5 domain; they appeared to be particularly clustered at or near the V3 loop (De Vreese et al., 1996b).
Thus, the HIV glycoprotein gp120 was suggested as the target of the bicyclams, but the specific site and mode of interaction with gp120 remained elusive. values of 25-50 µM of R3G and 100 µM for R4K without being toxic for the cells up to 1 mM concentrations (15) . However, the potential anti-HIV activity of R4K and R3G
and their mechanism of action in cell culture had not been described. We have found that R4K and R3G were able to inhibit HIV replication in a dose-dependent manner and to interact with CXCR4, thus impeding HIV-1 fusion and entry into CD4-positive cells.
MATERIALS AND METHODS
Compounds, viruses and cells. The synthesis, purification and chemical characterization of the L-arginine-aminoglycoside conjugates (Fig. 1 ) have been recently described (13) (14) (15) . R4K is an arginine-kanamycin A conjugate containing four arginine residues per molecule. The arginine-gentamicin conjugate mixture (R3G)
consists of tri-arginine substituted gentamicin C isomers. GB4K is structurally similar to R4K, but has γ-guanidinobutyric acid residues instead of L-arginine conjugated to a kanamycin A core. SDF-1α was purchased from Peprotech (London, UK). 
RESULTS
Anti-HIV activity of L-arginine-aminoglycoside conjugates. The comparative effects of seven compounds against HIV-1 NL4-3 are presented in Table 1 . Compounds R3G and R4K were both active at 50% effective concentrations (EC 50 ) of 15 µM and 31 µM, respectively. The 50 % cytotoxic concentrations (CC 50 ) were calculated to be >1130 µM and >3940 µM for R4K and R3G respectively. The chemokine SDF-1α was active at EC 50 of 0.04 µM while the CXCR4 antagonist AMD3100 was active at EC 50 of 0.01 µM. Conversely, compounds R2Gl, which contains two L-arginine residues conjugates to a monosaccharide core, and GB4K, which contains four γ-guanidinobutyric residues, did not show any significant anti-HIV activity. R3G, the most active in the aminoglycoside-arginine conjugate series, was likewise active against the X4 HIV-1 RF; the X4 HIV-1 clinical isolate AOM, which is resistant to AZT, and the R5 HIV-1 Ba-L strain. AMD3100 was inactive against HIV-1 Ba-L, while the reverse transcriptase inhibitor AZT was active against all HIV-1 strains tested except against HIV-1 AOM. The NL4-3 AMD3100-resistant virus was cross-resistant to SDF-1α (>25-fold)
to R4K (>4-fold) and R3G (>9-fold), suggesting that these compounds share a similar mode of action.
Interaction with CXCR4 receptor. To elucidate whether the anti-HIV activity of aminoglycoside-arginine conjugates is due to their interaction with CXCR4, we tested the capacity of the various analogs to inhibit the binding of an MAb to CXCR4 (12G5). SDF-1α, the natural ligand of CXCR4, and AMD3100, a CXCR4 antagonist that is active as an HIV-1 inhibitor, were used for the comparison. Table 2 (Fig.2) . To evaluate further the interaction of aminoglycoside-arginine conjugates with CXCR4, we tested the capacity of SDF-1α to induce an intracellular Ca 2+ signal in the presence of these conjugates. Both R3G and R4K inhibited the SDF-1α-dependent Ca Concentration (µg/ml) p24 antigen bound (pg/ml) may be designed to exert an anti-HIV activity through distinct mechanisms of action at early stages of infection.
Aminoglycoside-arginine conjugates were designed as specific TAR RNA binders, based on the idea that a combination of two RNA-binding patterns, aminoglycoside and peptide may be effective. These conjugates displayed high affinity and specificity TAR RNA binding in vitro, along with low cytotoxicity and antilentiviral potency in the model system of EIAV (Malmquist)-infected equine fibroblasts (14, 15) . We have found that the lead compounds R3G and R4K have anti-HIV activity at the micromolar range (EC 50 15 µM for R3G and 31 µM for R4K against the HIV-1 NL4-3 strain), with undetected cytotoxicity at the active concentrations (CC 50 was >3940 µM for R3G and 1130 µM for R4K ). Here, we suggest that the inhibitory capacity of these compounds is due to their cationic nature. Still unclear is why the cationic compounds R2Gl (containing two arginine residues) and GB4K
(containing four γ-guanidinobutyric residues and is structurally similar to R4K) are devoid of the antiviral effect observed with R4K and R3G. It is possible that the number a position of nitrogen residues in the molecule affects the antiviral activity. and it has no anti-HIV activity against virus strains that do not use CXCR4. However, the AMD3100-resistant strain was also cross-resistant to the binding inhibitors dextran sulfate and AR177 (25) , presumably because the amino acid changes in the gp120
protein that confer resistance to AMD3100 also alter the capacity of inhibitors of virus binding to function effectively (25) . In turn, virus strains that are resistant to anti-HIV agents that act at later stages of infection (i.e. reverse transcriptsase or later) are sensitive to AMD3100 (28) . Thus, the early stages of infection appear to be the time/site of action of aminoglycoside-arginine conjugates. This is further confirmed by the capacity of R3G and R4K to inhibit the binding of HIV particles to CD4 + cells, regardless of the coreceptor usage of the HIV strains used. The inhibitory activity on virus binding explains the anti-HIV activity of the most potent anti-HIV agent, R3G, against the R5 HIV-1 Ba-L strain (Table 1) despite of its lack of interaction with CCR5
( Fig. 2) . Although aminoglycoside-arginine conjugates are proven to be efficient and specific TAR RNA binders in vitro and possess an anti-EIAV activity in cell culture (14, 15) , HIV trans-ativation inhibition by the conjugates in vivo must be the subject for further studies. Here, we can state another mechanism of their antiviral activity through a bimodal action: blockade of CXCR4 and inhibition of virus binding to cells. A similar type of action could not be assigned to their anti-EIAV activity, since the Malmquist derivative of Wyoming strain used as a model lentivirus is avirulent and is incapable to infect directly equine fibroblasts (15).
In conclusion, our results support the idea that the cationic nature of known CXCR4 antagonists is necessary for their biological effect. Aminoglycoside-arginine conjugates R3G and R4K are novel lead compounds with moderate anti-HIV activity and low cytotoxicity. Future studies would be directed to design modifyed aminoglycoside-arginine conjugates with increased anti-HIV potency relative to that of R3G and R4K. In turn, it will be necessary to demonstrate that blockade of CXCR4 is a valid therapeutic strategy without significant adverse effects (29, 30) . CXCR4 use by
HIV-1 appears to be a causal factor for CD4 + cell depletion (31, 32) . Coreceptordependent tropism of HIV-1 appears to be even more restricted in vivo than may be predicted from in vitro testing since dual-tropic (R5X4) strains such as 89.6 behave like X4 strains and may be potently inhibited by CXCR4 antagonists in ex vivo cultures (33) .
Furthermore, blockade of CXCR4 prevented the evolution of HIV clinical isolates into CXCR4-using strains (34) or gp120-mediated apoptosis (35, 36) . These outstanding findings warrant the examination of CXCR4 antagonists as anti-HIV agents. 
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